Table 1.
Characteristics of included studies
| Study ID | Country | Rapid Kit | Mean Age (year) | No. of Patients | Source |
|---|---|---|---|---|---|
| Agulló et al. | Spain | Panbio COVID-19 Ag-RDT | 36.7 | 659 | NP, Nasal, Saliva, Nasal + saliva samples |
| Abdelrazik et al. | Egypt | BIOCREDIT COVID-19 Ag kit | NR | 310 | NP swab |
| Albert et al. | Spain | Panbio™COVID-19 Ag | 20.5 | 412 | NP swab |
| Ciotti et al. | Italy | COVID-19 Ag Respi‐Strip (Coris BioConcept) | 53.14 | 50 | NP swab |
| Kohmer et al. | Germany | R-Biopharm, Roche, NADAL, LumiraDx | NR | 100 | NP swab |
| Linares et al. | Spain | Abbott Rapid Diagnostic Jena GmbH | NR | 255 | NP swab |
| Nalumansia et al. | Uganda | STANDARD Q COVID-19 Ag | 34 | 262 | NP swab |
| Pilarowski et al. | USA | Abbott BinaxNOWTM COVID-19 Ag | NR | 217 | anterior swab |
| Salvagno et al. | Italy | Roche | 46 | 321 | NP |
| Schildgen et al. | Germany | RapiGEN (Gyeonggi-do, Korea), Abbott (Cologne, Germany), Roche | NR | 73 | throat washing and bronchoalveolar fluids |
| Scohy et al. | Belgium | COVID-19 Ag Respi-Strip (Coris Bioconcept) | 52.25 | 148 | NP |
| Toptan et al. | Germany | R-Biopharm | NR | 70 | NP |
| Torres et al. | Spain | 42.5 | 634 | NP | |
| CK Mak et al. | China | BIOCREDIT COVID-19 Ag | NR | 35 | NP aspirate and throat swab, NP and throat swab, sputum, throat saliva |
| Prince-Guerra et al. | USA | BinaxNOW antigen | 46.75 | 3419 | Anterior nasal swabs |
Abbreviations: NP nasopharyngeal, NR not reported